Tempus AI, Inc. (TEM)
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
Tempus AI (TEM) Reports Q1 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.
Tempus AI Nears Profitability as Operating Leverage Emerges
TEM nears profitability as gross profit surges and EBITDA turns positive, but persistent GAAP losses keep focus on long-term operating leverage.
Tempus AI Expands Strategic Partnership Amid Oncology Boom
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
TEM Stock Gains 17.9% in a Year: Time to Buy, Hold or Sell?
Tempus AI rides on diagnostics growth, AI-driven data demand, and pricing gains - but persistent losses and valuation questions complicate the buy-or-sell call.
What's Driving TEM Data and Applications Arm's Robust Growth?
Tempus AI's data arm surges with 69.5% Insights growth, $1.1B+ contracts, and AI-driven expansion fueling strong revenue outlook and customer retention gains.
Tempus AI: A Dual-Engine AI Model
Tempus AI is a diagnostics and data platform leveraging a large healthcare dataset to inform clinical decision-making. Strong 2025 performance driven by diagnostics growth, oncology re-acceleration, and Ambry Genetics acquisition. AI model reaching “critical mass” with 450+ petabytes of data, enabling new product expansion.
Tempus AI Stock Gains Following the ALERT Trial Result Announcement
TEM jumps after ALERT trial shows EHR alerts boost timely valve care, improving evaluations and interventions for aortic stenosis and MR patients.
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as sequencing and reimbursement expand.
